NEW YORK—Hill & Knowlton New York’s healthcare practice has been selected by Sankyo Pharma to represent its GlucoWatch brand, with a budget of nearly seven figures. The GlucoWatch G2 Biographer is an automatic, continuous, non-invasive glucose-monitoring system that is worn like a watch.
GlucoWatch joins two other Sankyo Pharma brands already on H&K New York’s Healthcare roster of clients. WelChol, Sankyo Pharma’s non-systemic cholesterol-lowering medication, has been an H&K client since April 2000; Sankyo’s hypertension treatment, Benicar, has been a client since August 2001.
“Our long-standing relationship with Hill & Knowlton was a major factor in our decision. We have grown to rely on the firm’s proven ability to deliver great results,” said senior brand manager Alecia Partridge. “With GlucoWatch, H&K put together a comprehensive program for us that was right on strategy.”
The campaign will be directed by Patricia Bifulco, senior managing director and Sankyo relationship manager and will involve media relations and marketing support for ongoing promotional activity.